Navigation Links
Ultrasound Transducer Disinfection in Many Cases Insufficient
Date:12/11/2008

HAMBURG, Germany, December 11 /PRNewswire/ --

- New 'Trophon EPR' Device Offers Unique Solution

Current methods of ultrasound transducer disinfection are in many cases not sufficient for clinical practice. This is the latest alarming result issued by the Center for Disease Control and Prevention (CDC), the leading US public health agency, in its recently published Guideline for Disinfection and Sterilization in Healthcare Facilities (1). The guideline is the CDC's response to the rapidly evolving epidemiology of hospital-acquired infections such as Clostridium Difficile (2) or MRSA (3).

In light of this global threat, and with regard to the millions of ultrasound examinations conducted each day, Nanosonics' newest product innovation represents a long-needed milestone in the development of medical devices: due to its unique technology, the Trophon EPR completely satisfies all requirements of the new CDC guideline.

Whereas current methods for high-level disinfection of contaminated transvaginal and transrectal transducers (e.g. aldehydes, alcohol or chlorine) show considerable drawbacks, the Trophon EPR has been custom designed to disinfect intracavity and surface ultrasound transducers, while combining speed, safety and convenience. It delivers high-level disinfection plus (HLD+), including sporicidal efficacy, in only six minutes operating time. The fully automated device can be used directly at the point of care, is easy to operate and is environmentally friendly, leaving water and oxygen as the only by-products.

"We recognised the danger presented by the inadequate disinfection of ultrasound transducers, and know that the Trophon EPR will be indispensable for the urgently needed hygiene necessary in the medical sector, to guarantee the safety of each and every patient", explained David Radford, Director and CEO of Nanosonics Limited, Australia, prior to the impending market launch.

The product technology has been validated by major OEM's (e.g. Philips Healthcare and Siemens Medical Solutions) and dealer commitments have already been approved in several European countries. The European launch of the Trophon EPR is scheduled to start in the first half of 2009. An application for FDA regulatory approval (510k) is on target for lodgement in December 2008, with anticipated approval later in 2009 allowing marketing within North America. For more information about Nanosonics, the Trophon EPR and its platform technology (NanoNebulant(TM)) please visit the Company's websites at http://www.nanosonics.eu and http://www.trophon.com.au.

About Nanosonics

The company is of Australian origin, located in Alexandria, Sydney, with European headquarters in Hamburg, Germany. Nanosonics has been listed on the Australian Securities Exchange (NAN) and Frankfurt Stock Exchange (OQM) since 2007.

The company owns intellectual property relating to unique disinfection and sterilisation technologies, which can be suited to a variety of markets including the healthcare industry, food processing, room and space decontamination, and manufacturing.

Nanosonics is currently focused on developing infection control solutions for the global healthcare market. Initial applications are designed for the reprocessing of reusable medical instruments. The Trophon EPR is specifically designed to disinfect intracavity and surface ultrasound probes. Based on the NanoNebulant(TM) technology it surpasses the limitations of current methods by killing the most resilient micro-organisms, in a fast, safe and convenient way.

(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee. Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008. http://www.cdc.gov/ncidod/dhqp/sterile.html.

(2) Association for Professionals in Infection Control and Epidemiology (APIC). Press release, Orlando, 11 November 2008: Intestinal infection afflicts 13 of 1,000 hospital patients; infection rates 6.5-20 times greater than previous estimates, new study says.

(3) Orsi GB. MRSA: an old and new enemy. Healthcare Infection 2008; 13:73-75.

    World Headquarters
    Nanosonics Ltd.
    Unit 24, 566 Gardeners Road
    Alexandria NSW 2015
    Australia
   http://www.nanosonics.com.au

    European Headquarters
    Nanosonics Europe GmbH
    Falkenried 88, House E
    20251 Hamburg
    Germany
   http://www.nanosonics.eu

    Media Contact Europe
    pluspool GmbH
    Nikola Heimann
    Ballindamm 26
    20095 Hamburg
    Germany
    nikola.heimann@plus-pool.de
    +49-40-35-54-36-24


'/>"/>
SOURCE Nanosonics Europe GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
2. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
3. MedPro Installs 1000th Ultrasound System Worldwide
4. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
5. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
6. Siemens Showcases New ACUSON S2000 Ultrasound System, as Well as Worlds First Pocket Ultrasound System
7. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
8. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
9. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
10. ALOKA to Introduce New ProSound Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida
11. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  HUYA Bioscience International, ... China,s pharmaceutical innovations, announced today ... Sciences Innovation and Investment Company (referred to as CAS ... biomedical innovations discovered by leading scientists at CAS to ... HUYA is the first company to have ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... or the "Company"), today announced that Cameron ... ("Kingsdale"), has resigned from its Board of Directors.  ... to securities regulations that have limited both his ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Factor (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® ... serum base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 /PRNewswire/ ... to grow at a CAGR of around 7.5% ... billion by 2025. Some of the prominent trends ... population, growing incidences of diseases & graft transplant ... Based on Material the market is categorized into ...
Breaking Biology Technology:
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):